Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity Therapeutics is developing integrated platforms, to target diseases caused by protein misfolding and is initially focused on discovering disease-modifying therapies for patients with Alzheimers disease, Parkinsons disease and ALS.
Yumanity Therapeutics Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/yumanity-therapeutics” connections=”true” suffix=””]
Yumanity three integrated platforms are: (1). Several proprietary ultra high-throughput, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; (2). A human neuronal platform, in which neurons produced from the stem cells of patients with disease-causing genetic mutations are used to validate the molecules discovered in yeast; and, (3). A drug-target identification platform that exploits the power of yeast genetics and protein network analyses to elucidate mechanisms of action for pathology correcting molecules as new chemical entities are discovered.
In June 2016, Yumanity Therapeutics signed a partnership with the New York Stem Cell Foundation Research Institute, a non-profit organization, accelerating cures for major diseases through stem cell research, to generate induced pluripotent stem cell (iPSC) lines for the discovery on new medicines in neurodegenerative diseases.
In Feb 2016, Yumanity Therapeutics raised $45 Mn in Series A round, led by Fidelity Management & Research Company with participation by Redmile Group, Alexandria Venture, Biogen, Sanofi-Genzyme BioVentures and Dolby Family Ventures.